Upper Endoscopy: Difference between revisions
No edit summary Tags: Mobile edit Mobile web edit |
No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 1: | Line 1: | ||
{{Stub Notice}} | {{Stub Notice}} | ||
https://pubmed.ncbi.nlm.nih.gov/9768765/ | [https://pubmed.ncbi.nlm.nih.gov/9768765/ Gastric contents in children presenting for upper endoscopy] | ||
Chehade M, Dellon ES, Spergel JM, et al. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age. The New England journal of medicine 2024;390(24):2239-2251. (In eng). DOI: 10.1056/NEJMoa2312282. | |||
2. Rothenberg ME, Dellon ES, Collins MH, et al. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 2023;8(11):990-1004. (In eng). DOI: 10.1016/s2468-1253(23)00204-2. |
Latest revision as of 12:24, 23 July 2024
This is a Stub Notice. This page has not been completed. You can work on this page by signing in and going to the Edit tab. Thanks for helping to make PedsAnesthesia.Net Wiki useful.
Go to the Main Page to see the Topic Outline.
Go to the Generalized Suggested Outline for information on case-specific details for each page.
Go to the Test Page for examples on how to use references in the page.
Relevant Article Depot:
Gastric contents in children presenting for upper endoscopy
Chehade M, Dellon ES, Spergel JM, et al. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age. The New England journal of medicine 2024;390(24):2239-2251. (In eng). DOI: 10.1056/NEJMoa2312282.
2. Rothenberg ME, Dellon ES, Collins MH, et al. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 2023;8(11):990-1004. (In eng). DOI: 10.1016/s2468-1253(23)00204-2.